Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial    symbols : EBS    save search
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
Published: 2021-08-25 (Crawled : 11:00) - globenewswire.com
EBS | News | $2.165 -5.46% 390K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 2.91% C: 2.5%
covid treatment phase 3 trial merge
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
Published: 2021-04-02 (Crawled : 12:15) - globenewswire.com
EBS | News | $2.165 -5.46% 390K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
covid treatment topline phase 3 trial merge
Gainers vs Losers
54% 46%

Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M twitter stocktwits trandingview |
Consumer Services
CZOO | $11.04 121.24% 9.6M twitter stocktwits trandingview |

BOF | $2.05 75.21% 78M twitter stocktwits trandingview |

AMST | $3.2 60.0% 63M twitter stocktwits trandingview |
Technology Services
LICN | $0.8592 53.43% 13M twitter stocktwits trandingview |

WIMI | $1.05 44.75% 13M twitter stocktwits trandingview |
Technology Services
TROO | $1.51 38.53% 5.6M twitter stocktwits trandingview |
Manufacturing
MULN | News | $3.675 34.62% 11M twitter stocktwits trandingview |
Information
RILY | $27.91 28.5% 8.9M twitter stocktwits trandingview |
Finance
WHLM | $6.43 26.58% 580K twitter stocktwits trandingview |
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.